J&J Procrit Documents Subpoenaed By HHS Inspector General
This article was originally published in The Pink Sheet Daily
The subpoena requests documents related to sales and marketing of the anemia treatment, Johnson & Johnson says. Procrit is also under scrutiny by the New York Attorney General.
You may also be interested in...
Procrit, Risperdal and four other leading J&J pharmaceutical brands are the subject of a document request from New York Attorney General Eliot Spitzer. J&J is already facing two federal investigations into marketing practices.
OPM appears to be conducting a wide-ranging investigation into mental health drug marketing. Forest, J&J and Wyeth have received subpoenas from the agency that oversees Federal Employees Health Benefits Program.
FDA’s draft guidance on systemic lupus erythematosus drug development lists four possible claims that the agency “may be willing to approve”: reduction in disease activity; organ-specific lupus treatment; complete clinical response/remission; and reduction in flares.